NUVL Chief Development Officer executes 10b5-1 plan: 4,000-share exercise and sales
Rhea-AI Filing Summary
Nuvalent insider transactions on 09/29/2025: Darlene Noci, Chief Development Officer, executed transactions under a Rule 10b5-1 plan adopted on November 18, 2024. She exercised a stock option to acquire 4,000 shares at an exercise price of $27.85 and contemporaneously sold 4,000 Class A common shares in multiple block sales at weighted average prices ranging from $81.39 to $84.92 across several lots.
Following these transactions the Form 4 reports 48,034 shares of Class A common stock beneficially owned and 4,000 shares subject to the option exercised, with the filing also showing 126,329 derivative securities beneficially owned following the reported transactions. The reporting attorney-in-fact signed the form on 10/01/2025.
Positive
- Transactions effected under a Rule 10b5-1 plan, indicating pre-planned, compliant insider trading
- Detailed weighted-average sale price disclosures and offer to provide per-trade breakdowns to the SEC or shareholders
Negative
- Net reduction of direct holdings by 4,000 Class A shares following the reported sales
- Significant selling at market prices could be interpreted by some investors as reduced insider share ownership (explicit fact from filing)
Insights
TL;DR: Routine insider exercise and sales under a pre-existing 10b5-1 plan; no new compensation grant or extraordinary event disclosed.
The Form 4 documents an option exercise at an exercise price of $27.85 for 4,000 shares and simultaneous sales of 4,000 Class A shares executed in multiple transactions with weighted average sale prices reported in footnotes as $81.39, $82.33, $83.20, $84.53 and $84.92 for separate blocks. The filing explicitly states these transactions were effected pursuant to a Rule 10b5-1 plan adopted November 18, 2024. Following the transactions the reporting person holds 48,034 Class A shares and 4,000 shares underlying the exercised option, and the form reports 126,329 derivative securities beneficially owned. The activity appears procedural and compliant with a pre-established trading plan, with no additional compensatory or corporate actions disclosed in this filing.
TL;DR: Disclosure is complete and cites a 10b5-1 plan, indicating governance compliance for scheduled insider trades.
The filing clearly identifies the reporting person as the Chief Development Officer and notes the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024, which is a standard mechanism for pre-authorized insider sales. The Form 4 provides weighted-average sale prices and offers to furnish detailed per-trade breakdowns to the SEC or shareholders on request, which aligns with good disclosure practice. There is no indication in the form of any amendment, special grant, or change in employment terms; the filing is a routine insider disclosure rather than a governance event that alters board or executive composition.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | -- |
| Exercise | Class A Common Stock | 4,000 | $27.85 | $111K |
| Sale | Class A Common Stock | 1,224 | $81.39 | $100K |
| Sale | Class A Common Stock | 522 | $82.33 | $43K |
| Sale | Class A Common Stock | 754 | $83.20 | $63K |
| Sale | Class A Common Stock | 1,083 | $84.53 | $92K |
| Sale | Class A Common Stock | 417 | $84.92 | $35K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.74 to $81.72, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.76 to $82.67, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.76 to $83.75, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.88 to $84.87, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.88 to $85.02, inclusive. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
